{
  "meta": {
    "title": "Neet_Pg_2024",
    "url": "https://brainandscalpel.vercel.app/neet-pg-2024-ab42e284.html",
    "scrapedAt": "2025-11-30T07:36:17.373Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">4 tablets of artesunate 50 mg + 6 tablets of primaquine 2.5 mg</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">4 tablets of artesunate 50 mg + sulphadoxine 1500 mg + 6 tablets of primaquine 2.5 mg</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">4 tablets of artesunate 50 mg + sulphadoxine 1500 mg + 6 tablets of primaquine 7.5 mg</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">4 tablets of artesunate 50 mg + 6 tablets of primaquine 7.5 mg</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 36-year-old man from North India presents with a mixed infection of Plasmodium vivax and Plasmodium falciparum. What is the expected dosage for treatment given on the second day?</span></p>",
      "unique_key": "DT1324803",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324803,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>For the treatment of mixed malaria infection with <strong>Plasmodium vivax</strong> and <strong>Plasmodium falciparum</strong>, the treatment regimen typically includes artesunate for blood stages &amp; <strong>P. falciparum</strong> and primaquine for liver stages &amp; <strong>P. vivax</strong>.</p>\r\n<p><strong>Treatment of Malaria:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250829c9986b79-26f0-41ef-9e7c-df378d172a91.png\">\r\n<p><strong>Reference:</strong></p>\r\n<ol>\r\n<li><a href=\"https://www.researchgate.net/publication/369931382_Burden_of_Drug_Resistance_in_vivax_Malaria_in_India_-_A_Brief_Update\" target=\"_blank\">https://www.researchgate.net/publication/369931382_Burden_of_Drug_Resistance_in_vivax_Malaria_in_India_-_A_Brief_Update</a></li>\r\n</ol>",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Bortezomib</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Lenalidomide</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Daratumumab</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Elotuzumab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs used in the treatment of multiple myeloma is associated with the reactivation of herpes zoster?</span></p>",
      "unique_key": "DT1324805",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324805,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The drug that is used to treat <strong>multiple myeloma</strong> and is known to cause <strong>reactivation of herpes zoster</strong> is <strong>Bortezomib, </strong>a proteasome inhibitor used in the treatment of multiple myeloma.</p>\r\n<p>It has been associated with an increased risk of <strong>herpes zoster reactivation</strong> due to its immunosuppressive effects.</p>\r\n<ul>\r\n<li>Given as IV/SC.</li>\r\n<li><strong>Adverse effects: </strong>Thrombocytopenia, Peripheral neuropathy, Neutropenia, Anaemia, DIC.</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Lenalidomide (Option B)</strong> is an immunomodulatory analogue of thalidomide &amp; is the DOC in MDS associated with 5q deletion. It suppresses bone marrow and is associated with significant leukopenia.</p>\r\n<p><strong>Daratumumab (Option C) (</strong>against<strong> CD-38)</strong> and <strong>Elotuzumab (Option D)</strong> <strong>(</strong>against <strong>SLAMF7)</strong> are monoclonal antibodies used in the treatment of multiple myeloma, and while they may cause various side effects, they are less commonly associated with <strong>herpes zoster reactivation</strong> compared to <strong>bortezomib</strong>.</p>",
      "correct_choice_id": 11,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">There is no allergic sensitization to aspirin and its metabolites</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Responds to Montelukast</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Occurs on exposure to only aspirin</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Occurs with exposure to other NSAIDs too that block COX-1</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient experiences breathing difficulty and nasal polyps after taking aspirin, with a similar past history. Which of the following statements about this condition is not true?</span></p>",
      "unique_key": "DT1324807",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324807,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation: </strong></p>\r\n<ul>\r\n<li>The condition described in the question is <strong>Aspirin-Exacerbated Respiratory Disease (AERD)</strong>, also known as <strong>Aspirin-Intolerant Asthma</strong> or <strong>Samter's Triad,</strong> which typically involves the combination of:\r\n<ul>\r\n<li><strong>Asthma</strong></li>\r\n<li><strong>Nasal polyposis</strong></li>\r\n<li><strong>Aspirin intolerance</strong></li>\r\n</ul>\r\n</li>\r\n<li>In AERD, the inhibition of <strong>COX-1</strong> by aspirin or NSAIDs leads to reduced production of prostaglandins, particularly <strong>prostaglandin E2 (Page E2)</strong>, which normally helps regulate inflammation.</li>\r\n<li>This leads to an increase in the production of <strong>leukotrienes</strong>, potent inflammatory mediators that cause bronchoconstriction and airway inflammation, worsening asthma and causing the symptoms of AERD.</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>There is no allergic sensitisation to aspirin and its metabolites (Option A): </strong>The condition is not due to classic IgE-mediated allergy to aspirin or its metabolites. Instead, it is believed to be a result of the inhibition of COX-1 (cyclooxygenase 1) by aspirin, which leads to an imbalance in leukotriene and prostaglandin production, triggering respiratory symptoms.</p>\r\n<p>It can also be triggered by other <strong>nonsteroidal anti-inflammatory drugs (NSAIDs)</strong>, especially those that inhibit COX-1, such as ibuprofen, naproxen, and other NSAIDs. The condition is not limited to aspirin alone <strong>(Option D &amp; C).</strong></p>\r\n<p><strong>Responds to Montelukast (Option B):</strong> Montelukast, a leukotriene receptor antagonist, is commonly used to manage symptoms in AERD as it helps reduce inflammation and bronchoconstriction associated with the condition.</p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Tolterodine</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Telenzipine</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Ipratropium</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Tiotropium</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 66-year-old female presents with urinary incontinence along with dementia and cognitive decline. Which of the following is a useful treatment for urinary incontinence in this patient?</span></p>",
      "unique_key": "DT1324812",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324812,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>For the given patient presenting with <strong>urinary incontinence</strong> along with <strong>dementia</strong> and <strong>cognitive decline</strong>, the most appropriate treatment option from the given choices would be <strong>Tolterodine.</strong></p>\r\n<ul>\r\n<li>It is an <strong>antimuscarinic</strong> medication used to treat <strong>overactive bladder</strong> and <strong>urinary incontinence</strong>. It exhibits bladder selectivity &amp; works by inhibiting the muscarinic receptors in the bladder, reducing bladder contractions, and helping to control urinary incontinence.</li>\r\n<li>Bladder selectivity is beneficial for patients with cognitive decline or dementia as it reduces the risk of adverse effects.</li>\r\n<li><strong>Other muscarinic antagonists for urinary incontinence:</strong>\r\n<ul>\r\n<li>Oxybutynin</li>\r\n<li>Trospium</li>\r\n<li>Solifenacin</li>\r\n<li>Darifenacin</li>\r\n</ul>\r\n</li>\r\n<li><strong>Solifenacin &amp; Darifenacin </strong>have selectivity for M3 receptors.</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Telenzipine (Option B)</strong> is a <strong>muscarinic receptor antagonist</strong>, but it is <strong>not commonly used for urinary incontinence</strong>. It is mainly used for treating acid-peptic disease by selectively antagonising the M1 receptor.</p>\r\n<p><strong>Ipratropium (Option C)</strong> and <strong>tiotropium (Option D)</strong> are <strong>anticholinergic drugs</strong> used primarily for the treatment of <strong>chronic obstructive pulmonary disease (COPD)</strong> or <strong>asthma</strong>. They are <strong>not used for urinary incontinence</strong>.</p>\r\n<ul>\r\n<li><strong>Tiotropium - </strong>Long-acting, M1 &amp; M3 selective</li>\r\n<li><strong>Ipratropium -</strong> Short-acting</li>\r\n</ul>",
      "correct_choice_id": 31,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Clearance</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Volume of distribution</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Plasma half-life</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Bioavailability</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Lignocaine is used as a loading dose for the treatment of arrhythmias. The loading dose depends on which of the following factors?</span></p>",
      "unique_key": "DT1324815",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324815,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The <strong>loading dose</strong> of a drug depends upon the <strong>volume of distribution:</strong></p>\r\n<ul>\r\n<li>A drug's loading dose is given to achieve a target plasma concentration quickly when the treatment requires an immediate therapeutic response.</li>\r\n<li>Loading dose depends on the <strong>volume of distribution</strong> of a drug<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202508081bf3f5a3-6e28-40d4-a430-a3642a088df7.png\"></li>\r\n</ul>\r\n<p><strong>Learning Objective:</strong></p>\r\n<ul>\r\n<li>Maintenance dose mainly depends on the <strong>clearance/plasma half-life</strong> of a drug.</li>\r\n</ul>  <img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/2025080848088858-ba3a-4759-95d0-da9cae1a1af2.png\">",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Furosemide</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Mannitol</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrochlorothiazide</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with hypertension and chronic kidney disease presents with recurrent episodes of renal colic. Which diuretic is most suitable for use in this clinical scenario?</span></p>",
      "unique_key": "DT1324819",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324819,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>A hypertensive patient with chronic kidney disease (CKD) experiencing frequent attacks of renal colic would benefit from <strong>Hydrochlorothiazide</strong>, a thiazide diuretic.</p>\r\n<ul>\r\n<li>It helps manage <strong>hypertension</strong> and can reduce <strong>calcium excretion</strong> in urine, which is beneficial for preventing <strong>calcium-based kidney stones</strong>, a common cause of <strong>renal colic</strong>.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250829ec1c6297-eaf0-4f9b-a01e-2e81e3f387f7.png\"></li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Furosemide (Option A)</strong> is a <strong>loop diuretic</strong> that indeed causes <strong>increased calcium excretion</strong> in the urine, which can <strong>exacerbate symptoms of renal colic</strong>.</p>\r\n<p><strong>Mannitol (Option B)</strong>, an <strong>osmotic diuretic</strong>, is used in <strong>acute settings</strong> and is not suitable for chronic conditions like CKD and renal colic.</p>\r\n<p><strong>Spironolactone (Option D)</strong>, a <strong>potassium-sparing diuretic</strong>, is typically used for <strong>heart failure</strong> or <strong>aldosterone excess</strong> but not for preventing kidney stones or controlling hypertension in CKD.</p>",
      "correct_choice_id": 53,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Clopidogrel</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Amino-caproic acid</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Tenecteplase</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Heparin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Identify the drug marked as \"X\"in the given image.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202508089b1c8b9c-e271-45a6-ae4b-e83ab2777fed.png\"></span></p>",
      "unique_key": "DT1324820",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324820,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Amino-caproic acid</strong> is an <strong>antifibrinolytic agent</strong> that works by inhibiting the activation of <strong>plasminogen</strong> to <strong>plasmin</strong>, thus preventing the breakdown of fibrin in blood clots.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025082819e2b9fe-c5b3-48cf-b084-327c3fbf4fdd.png\">\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Clopidogrel (Option A)</strong> is an <strong>antiplatelet agent</strong> that prevents platelet aggregation by inhibiting the ADP receptor on platelets. It does not affect the conversion of plasminogen to plasmin.</p>\r\n<p><strong>Tenecteplase (Option C)</strong> is a <strong>thrombolytic agent</strong> that facilitates the conversion of plasminogen to plasmin, promoting the breakdown of clots. It is the opposite of <strong>Amino-caproic acid</strong> in terms of its action.</p>\r\n<p><strong>Heparin (Option D)</strong> is an <strong>anticoagulant</strong> that works by inhibiting thrombin and factor Xa to prevent clot formation, but it does not directly affect the conversion of plasminogen to plasmin.</p>",
      "correct_choice_id": 62,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Bisoprolol</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Pindolol</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Esmolol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following beta-blockers is effective in patients with reduced ejection fraction and has been shown to reduce mortality in chronic heart failure without causing long-term worsening of the condition?</span></p>",
      "unique_key": "DT1324823",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324823,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation: </strong></p>\r\n<p><strong>Bisoprolol</strong> is a cardioselective beta blocker that is beneficial in chronic heart failure with reduced ejection fraction (HFrEF). It helps improve heart function, reduce symptoms, and <strong>reduce mortality</strong> over time in heart failure patients.</p>\r\n<ul>\r\n<li>Beta-blockers that have been proven to improve the survival of patients with HFrEF/Chronic HF are\r\n<ul>\r\n<li><strong>Bisoprolol</strong></li>\r\n<li><strong>Metoprolol</strong></li>\r\n<li><strong>Carvedilol</strong></li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Propranolol (Option A)</strong> is a <strong>non-selective beta blocker</strong>, which blocks both beta-1 and beta-2 receptors. It is not typically preferred in heart failure with reduced ejection fraction as it may cause bronchospasm due to beta-2 receptor blockade and has less favourable long-term outcomes compared to cardioselective beta blockers like bisoprolol.</p>\r\n<p><strong>Pindolol (Option C)</strong> is a <strong>non-selective beta blocker</strong> with intrinsic sympathomimetic activity (ISA), meaning it partially stimulates beta receptors while blocking them. This property is generally not ideal in chronic heart failure, as it may not provide the same mortality benefits as other beta-blockers without ISA.</p>\r\n<p><strong>Esmolol (Option D)</strong> is a <strong>short-acting, cardioselective beta blocker</strong> typically used for acute conditions like arrhythmias and perioperative hypertension. It is not used for long-term management of chronic heart failure.</p>\r\n<p><strong>Learning Outcome:</strong></p>\r\n<p>The following 4 beta blockers are clinically tested and approved for the treatment of heart failure:</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025082862663758-51af-4a18-961e-75718abe606a.png\">",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">NK3 antagonist</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">NK1 agonist</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">NK1 antagonist</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">NK2 agonist</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A postoperative patient develops nausea and vomiting and is treated with aprepitant. What is the primary mechanism by which this drug exerts its antiemetic effect?</span></p>",
      "unique_key": "DT1324825",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324825,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Aprepitant</strong> is a <strong>neurokinin-1 (NK1) receptor antagonist</strong>. It works by blocking the action of <strong>substance P</strong>, a neurotransmitter that plays a key role in inducing nausea and vomiting.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025082949fba913-5e19-41b8-a383-a7f91b101073.png\">",
      "correct_choice_id": 83,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Resistance to both rifampicin and isoniazid with mutations in the inhA and katG genes</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Resistance to rifampicin but sensitivity to fluoroquinolones</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Resistance to rifampicin and sensitivity to isoniazid</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Resistance to both rifampicin and fluoroquinolones</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In the management of a patient diagnosed with multidrug-resistant or rifampicin-resistant tuberculosis, which of the following would be a suitable criterion for initiating bedaquiline therapy?</span></p>",
      "unique_key": "DT1324827",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324827,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>MDR-TB is resistant to <strong>at least isoniazid and rifampicin</strong>, which are the two most potent first-line anti-TB drugs. This includes strains with mutations in the <strong>inhA and katG</strong> genes, which are associated with <strong>isoniazid resistance</strong>.</p>\r\n<ul>\r\n<li>Bedaquiline is a new medication specifically developed for the treatment of MDR-TB.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/202508086fc45e4f-af59-443c-91db-87fd4c48ee36.png\">\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Resistance to Rifampicin but Sensitivity to Fluoroquinolones (Option B)</strong>: While resistance to rifampicin is a key factor in MDR-TB, the inclusion criterion for starting bedaquiline is more specific. Sensitivity to fluoroquinolones alone does not meet the criteria for bedaquiline use; it is usually considered in the broader context of multidrug-resistant TB, including resistance to both rifampicin and isoniazid.</p>\r\n<p><strong>Resistance to Rifampicin and Sensitivity to Isoniazid (Option C):</strong> Resistance to rifampicin and sensitivity to isoniazid would be classified as rifampicin-resistant TB rather than MDR-TB. Bedaquiline is typically used for MDR-TB, which involves resistance to both rifampicin and isoniazid, not just one.</p>\r\n<p><strong>Resistance to Both Rifampicin and Fluoroquinolones (Option D) </strong>suggests a more severe form of drug-resistant TB, potentially extensively drug-resistant (XDR-TB). Bedaquiline may still be used in such cases, but the initial criterion for starting it is based on MDR-TB, which includes resistance to both rifampicin and isoniazid.</p>\r\n<p><strong>Reference:</strong></p>\r\n<ol>\r\n<li><a href=\"https://www.ncbi.nlm.nih.gov/books/NBK247413/\" target=\"_blank\">Mono- and poly-resistant strains (drug-resistant TB other than MDR-TB) - Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis - NCBI Bookshelf</a></li>\r\n<li><a href=\"https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/featured-topics/new-treatment-tb\" target=\"_blank\">https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/featured-topics/new-treatment-tb</a></li>\r\n</ol>",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Calcium disodium EDTA</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Deferoxamine</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">British anti-lewisite (BAL)</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Penicillamine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following chelating agents is contraindicated in the treatment of iron poisoning?</span></p>",
      "unique_key": "DT1324828",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324828,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>BAL (Dimercaprol)</strong> is a chelator primarily used to treat poisoning by heavy metals such as arsenic, mercury, and lead. However, it is contraindicated in iron poisoning because it does not effectively bind to iron. It may displace iron from its binding sites, potentially worsening the toxicity. Therefore, using BAL in iron poisoning could exacerbate the condition rather than alleviate it.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202508286c4e88fb-ba2b-4ef2-9b73-36512b10448c.png\">",
      "correct_choice_id": 103,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Low molecular weight heparin (LMWH)</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Apixaban</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Rivaroxaban</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 29-week pregnant woman is diagnosed with deep vein thrombosis (DVT) based on Doppler findings and presents with calf tenderness. Which anticoagulant is most appropriate for treatment?</span></p>",
      "unique_key": "DT1324829",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324829,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<ul>\r\n<li><strong>Low molecular weight heparin (LMWH)</strong>, such as <strong>enoxaparin</strong>, is the preferred anticoagulant for treating DVT in pregnancy.</li>\r\n<li>It is safe, does not cross the placenta, and has a lower risk of causing heparin-induced thrombocytopenia (HIT) than unfractionated heparin.</li>\r\n<li>LMWH is also effective in preventing the extension of the thrombus and reducing the risk of pulmonary embolism, making it the standard treatment for DVT during pregnancy.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202508286b710898-2bb3-4b35-afe4-04b306a2dd3d.png\">\r\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025082816153355-5ca1-4e77-93e7-bb52532bceca.png\"><p><strong>Reference:</strong></p>\r\n<ol>\r\n<li><a href=\"https://www.ncbi.nlm.nih.gov/books/NBK430980/\">Antiphospholipid Syndrome - StatPearls - NCBI Bookshelf</a>&nbsp;</li>\r\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950440/#:~:text=The%20Royal%20College%20of%20Obstetricians,women%20who%20are%20breast%20feeding'.&amp;text=Similarly%2C%20ACCP%20guidelines%20(2012),in%20pregnancy%20or%20breast%20feeding.%20%20https://www.uptodate.com/contents/management-of-risks-of-prosthetic-valve\">Anticoagulants</a></li>\r\n</ol>",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Drug-induced hypercalcemia</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary hyperparathyroidism</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Small cell lung cancer</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Thymoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 64-year-old patient undergoing treatment with Mycophenolate mofetil (MMF) presents with a serum calcium level of 13.7 mg/dL and also has myasthenia gravis. What is the likely cause of the hypercalcemia in this patient?</span></p>",
      "unique_key": "DT1324832",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324832,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Thymoma</strong> is a tumor originating from the thymus gland and is frequently associated with myasthenia gravis <strong>(44%)</strong>.</p>\r\n<ul>\r\n<li>Hypercalcemia can occur in patients with thymoma due to the production of <strong>parathyroid hormone-related peptide (PTHrP)</strong> by the tumor or associated paraneoplastic syndromes.</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Drug-induced Hypercalcemia (Option A): </strong>Mycophenolate mofetil (MMF) is an immunosuppressant that is not typically associated with hypercalcemia. Drug-induced hypercalcemia is unlikely in this case, as MMF is not known to cause this side effect.</p>\r\n<p><strong>Primary Hyperparathyroidism (Option B)</strong> is a common cause of hypercalcemia. However, the association between myasthenia gravis and thymoma, along with the observed hypercalcemia, makes thymoma a more likely diagnosis in this context.</p>\r\n<p><strong>Small Cell Lung Cancer (Option C) </strong>is more commonly linked to ectopic hormone production, such as ACTH or ADH, rather than parathyroid hormone-related protein (PTHrP), which causes hypercalcemia. Additionally, there is no strong connection between myasthenia gravis and small-cell lung cancer, making it an unlikely cause in this patient.</p>",
      "correct_choice_id": 124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Reboxetine</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Tramadol</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Paroxetine</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Bupropion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which one of the following is an SNRI antidepressant drug?</span></p>",
      "unique_key": "DT1324833",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324833,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Reboxetine</strong> is a <strong>selective norepinephrine reuptake inhibitor (SNRI)</strong> and is used as an antidepressant. It affects norepinephrine reuptake exclusively and does not significantly impact serotonin levels.</p>\r\n<p><strong>Selective Norepinephrine Reuptake Inhibitors (SNRIs)</strong> primarily target the reuptake of norepinephrine, increasing its levels in the synaptic cleft. These drugs are commonly used in the treatment of conditions such as depression and attention deficit hyperactivity disorder (ADHD). Some key SNRIs include:</p>\r\n<ul>\r\n<li>Desipramine</li>\r\n<li>Nortriptyline</li>\r\n<li>Reboxetine</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Tramadol (Option B)</strong> is an analgesic with weak serotonin and norepinephrine reuptake inhibition properties. However, it is primarily used for pain management, and its SNRI-like effects are secondary, not its primary function. Therefore, it is not classified as an SNRI.</p>\r\n<p><strong>Paroxetine</strong> <strong>(Option C) </strong>is a selective serotonin reuptake inhibitor (SSRI). It primarily inhibits serotonin reuptake and does not significantly affect norepinephrine, so it is not classified as an SNRI.</p>\r\n<p><strong>Bupropion (Option D)</strong> is a norepinephrine-dopamine reuptake inhibitor (NDRI), which primarily affects norepinephrine and dopamine reuptake. It does not significantly impact serotonin levels, so it is not considered an SNRI.</p>",
      "correct_choice_id": 131,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Clonidine</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Lisinopril</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Amlodipine</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Telmisartan</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with hypertension discontinued his antihypertensive medication due to complaints of dry mouth, dry eyes, and constipation. Shortly after stopping the drug, he presented with a hypertensive emergency, with blood pressure exceeding 180/120 mmHg. Which medication was he most likely taking?</span></p>",
      "unique_key": "DT1324835",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324835,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Clonidine </strong>is an <strong>alpha-2 adrenergic agonist</strong> used to treat hypertension. It works by decreasing sympathetic outflow, which lowers blood pressure. When clonidine is stopped abruptly, it can lead to a <strong>rebound increase in blood pressure (Withdrawal syndrome)</strong>, potentially causing a hypertensive emergency.</p>\r\n<ul>\r\n<li><strong>Withdrawal syndrome </strong>is characterized by various symptoms, including headache, apprehension, tremors, abdominal pain, sweating, and tachycardia.\r\n<ul>\r\n<li>Typically, this occurs 18 to 36 hours after stopping the medication</li>\r\n<li><strong>Management</strong>: Resume <strong>Clonidine administration</strong> and <strong>Phentolamine</strong> is considered the drug of choice for a hypertensive crisis</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Lisinopril (Option B)</strong> is an ACE inhibitor used to treat hypertension and heart failure. Discontinuing lisinopril does not typically lead to rebound hypertension. Common side effects include cough and elevated potassium levels, but dry eyes, dry mouth, or constipation are not associated with lisinopril. Thus, a hypertensive emergency after stopping lisinopril is unlikely.</p>\r\n<p><strong>Amlodipine (Option C)</strong> is a calcium channel blocker commonly used to manage hypertension and angina. Amlodipine does not cause rebound hypertension when stopped. Its side effects can include swelling, dizziness, and flushing, but dry eyes, dry mouth, or constipation are not common. Therefore, stopping amlodipine would not typically lead to a hypertensive emergency.</p>\r\n<p><strong>Telmisartan (Option D)</strong> is an angiotensin II receptor blocker (ARB). Similar to lisinopril, discontinuing telmisartan does not cause rebound hypertension. Common side effects include dizziness and hyperkalemia but not dry eyes, dry mouth, or constipation. A hypertensive emergency is unlikely to occur with the abrupt discontinuation of telmisartan.</p>",
      "correct_choice_id": 141,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Tesamorelin</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Somatropin</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Octreotide</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Pegvisomant</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which medication is indicated for managing lipodystrophy associated with HIV infection?</span></p>",
      "unique_key": "DT1324836",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324836,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Tesamorelin </strong>is a synthetic growth hormone-releasing hormone (GHRH) analogue that is used specifically for reducing abdominal fat in patients with <strong>HIV-associated lipodystrophy.</strong></p>\r\n<ul>\r\n<li>It works by stimulating the release of growth hormone, which helps to reduce visceral fat accumulation. It is the primary medication approved for this indication.</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Somatropin (Option B)</strong> is a<strong> recombinant growth hormone</strong> used to treat growth hormone deficiencies and growth disorders. While it may have some effect on body composition, it is not specifically indicated for HIV-induced lipodystrophy. Its use is broader and not targeted at managing fat distribution issues in HIV patients.</p>\r\n<p><strong>Octreotide (Option C)</strong> is a <strong>somatostatin analogue</strong> used to treat conditions like <strong>acromegaly</strong> and certain tumours. It is not used for HIV-induced lipodystrophy and works by inhibiting growth hormone release, which does not address the fat redistribution associated with HIV.</p>\r\n<p><strong>Pegvisomant (Option D) </strong>is a <strong>growth hormone receptor antagonist </strong>used to treat acromegaly by blocking the action of growth hormone at its receptor. It does not target fat redistribution or accumulation in HIV-induced lipodystrophy and is not appropriate for this condition.</p>",
      "correct_choice_id": 151,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">To correct the side effects of diphenoxylate</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">To enhance the antidiarrheal efficacy of diphenoxylate</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">To provide an additional antidiarrheal effect</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">To reduce the potential for abuse of diphenoxylate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Diphenoxylate is commonly prescribed for secretory diarrhoea in combination with atropine. What is the main purpose of adding atropine to this regimen?</span></p>",
      "unique_key": "DT1324837",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324837,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Diphenoxylate</strong> is an opioid derivative with antidiarrheal properties. It can potentially be abused due to its opioid-like effects, especially at higher doses.</p>\r\n<ul>\r\n<li><strong>To mitigate the risk of abuse</strong>, diphenoxylate is combined with atropine, an anticholinergic agent. The addition of atropine causes unpleasant side effects (such as dry mouth, blurred vision, and tachycardia) at higher doses, which discourages abuse of the medication.</li>\r\n</ul>",
      "correct_choice_id": 164,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">Nicotinamide</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">Atorvastatin</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">Fenofibrate</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">Cholestyramine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient being treated for hypertriglyceridemia develops flushing, gout, and elevated liver enzymes after starting medication. Which of the following drugs is most likely responsible for these side effects?</span></p>",
      "unique_key": "DT1324840",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324840,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Niacin (Nicotinamide) is commonly used to lower triglycerides and raise HDL cholesterol &amp; is associated with side effects like flushing, gout &amp; elevated liver enzymes.&nbsp;</p>\r\n<p><strong>Niacin:&nbsp;</strong></p>\r\n<p>Niacin is <strong>Vitamin B3 or nicotinic acid</strong>. It inhibits lipolysis in adipose tissue and <strong>ï¿¬</strong><strong>triglyceride production</strong> by the liver. It also increases <strong>HDL levels</strong>. Its use is limited by its side effects:</p>\r\n<ul>\r\n<li>Flushing (taking aspirin before niacin helps to reduce flushing)</li>\r\n<li>Dry skin</li>\r\n<li>Dyspepsia</li>\r\n<li>Hepatotoxicity presents with fatigue and weakness</li>\r\n<li>Hyperglycemia- it can indicate insulin resistance and should be used cautiously in those with diabetes</li>\r\n<li>Increases uric acid levels, hence contraindicated in gout</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Atorvastatin (Option B)</strong> is a statin used primarily to lower LDL cholesterol and triglycerides. While it can cause elevated liver enzymes and muscle-related issues (such as myopathy), it is not typically associated with flushing or gout.</p>\r\n<p><strong>Fenofibrate (Option C)</strong> is a fibrate that effectively lowers triglycerides. It can lead to elevated liver enzymes and muscle-related side effects, but flushing and gout are not commonly associated with its use.</p>\r\n<p><strong>Cholestyramine (Option D) </strong>is a bile acid sequestrant used to lower LDL cholesterol. It is mainly known to cause gastrointestinal issues like constipation, but it does not cause flushing, gout, or elevated liver enzymes.</p>",
      "correct_choice_id": 171,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">TMP</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">CMP</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">GMP</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">AMP</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The administration of methotrexate leads to decreased synthesis of which of the following nucleotides?</span></p>",
      "unique_key": "DT1324842",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324842,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Methotrexate</strong> is a folate analogue that inhibits the enzyme <strong>dihydrofolate reductase (DHFR)</strong>.</p>\r\n<ul>\r\n<li>DHFR is crucial for the conversion of dihydrofolate to tetrahydrofolate, a cofactor required for the synthesis of <strong>thymidylate (TMP)</strong>, which is necessary for DNA synthesis.</li>\r\n<li>By inhibiting this enzyme, methotrexate reduces the synthesis of TMP, leading to impaired DNA synthesis, particularly affecting rapidly dividing cells.</li>\r\n<li>Methotrexate does not directly inhibit the synthesis of CMP, GMP, or AMP to the same extent.<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGMCQ/20250808531d66fa-154d-49ce-acc1-a19a4b29dc87.png\"></li>\r\n</ul>",
      "correct_choice_id": 181,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Sugammadex</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Neostigmine</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Physostigmine</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Rivastigmine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a patient with renal failure who has received Vecuronium or Rocuronium, which of the following agents is typically used for reversal of the neuromuscular blockade?</span></p>",
      "unique_key": "DT1324844",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324844,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Neostigmine</strong> is an <strong>acetylcholinesterase inhibitor</strong> commonly used to reverse the effects of non-depolarising muscle relaxants like vecuronium and rocuronium.</p>\r\n<ul>\r\n<li>In patients with renal failure, neostigmine is preferred because it does not rely on renal excretion as much as sugammadex.</li>\r\n<li>Neostigmine works by increasing acetylcholine levels at the neuromuscular junction, outcompeting the muscle relaxant and reversing the blockade.</li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250829faaae410-e985-4ff7-9284-31ab00f829ef.png\">\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p>Although <strong>Sugammadex</strong> <strong>(Option A)</strong> is a highly effective reversal agent for vecuronium and rocuronium, it is contraindicated in patients with severe renal impairment. Since sugammadex is primarily excreted by the kidneys, its use in renal failure could lead to prolonged effects and potential accumulation.</p>\r\n<p><strong>Physostigmine (Option C) </strong>is not used to reverse neuromuscular blockades caused by vecuronium or rocuronium. It is mainly used to treat anticholinergic toxicity, as it can cross the blood-brain barrier.</p>\r\n<p><strong>Rivastigmine (Option D) </strong>is not used to reverse neuromuscular blockade. It is primarily used to treat cognitive symptoms in Alzheimer's disease and other dementias.</p>",
      "correct_choice_id": 192,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">Dicyclomine</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">Scopolamine</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">Galantamine</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">Rivastigmine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with inflammatory bowel disease experiences severe abdominal cramping. Which of the following drugs is most likely prescribed for its direct spasmolytic action on gastrointestinal smooth muscle?</span></p>",
      "unique_key": "DT1324852",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324852,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Dicyclomine </strong>is an antispasmodic medication that works by directly relaxing smooth muscles in the gastrointestinal tract, thereby reducing spasms and alleviating pain in conditions like irritable bowel syndrome (IBS).</p>\r\n<p><strong>Antispasmodic Anticholinergics:</strong></p>\r\n<p><strong>Scopolamine</strong>, by blocking muscarinic receptors in the GI tract, causes:</p>\r\n<ul>\r\n<li><strong>Reduced Tone and Motility: </strong>This slows down the passage of gastrointestinal contents.</li>\r\n<li><strong>Antispasmodic effect</strong>: Helps to alleviate spasms and cramps by reducing the tone and contractions of the gastrointestinal tract, but not as specific <strong>(Option B)</strong> as Dicyclomine in IBD.</li>\r\n</ul>\r\n<p><strong>Other antispasmodic anticholinergic drugs:</strong></p>\r\n<ol>\r\n<li><strong>Dicyclomine:</strong> Used as an antispasmodic for<strong> irritable bowel syndrome (IBS)</strong> and other gastrointestinal problems.</li>\r\n<li><strong>Valethamate:</strong> Used to hasten dilation of the cervix during labour and as a visceral antispasmodic for urinary, biliary, and intestinal colic.</li>\r\n</ol>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Galantamine</strong> <strong>(Option C)</strong> is a cholinesterase inhibitor primarily used in the treatment of Alzheimer's disease. It does not exert a direct spasmolytic effect on the gastrointestinal tract.</p>\r\n<p><strong>Rivastigmine</strong> <strong>(Option D) </strong>is another cholinesterase inhibitor used in Alzheimer's and Parkinson's disease. It has no direct spasmolytic effect on smooth muscle in the GI tract.</p>",
      "correct_choice_id": 201,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Mannitol</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Spironolactone</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Acetazolamide</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrochlorothiazide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient sustains a head injury in a road traffic accident and shows signs of elevated intracranial pressure (ICP). Which diuretic is the most suitable for reducing ICP in this scenario?</span></p>",
      "unique_key": "DT1324855",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324855,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Mannitol </strong>is an osmotic diuretic commonly used in clinical practice to reduce increased intracranial pressure (ICP). It works by drawing water out of the brain and into the bloodstream, thereby reducing cerebral oedema and lowering ICP.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250829bb90dfcd-5a92-4519-a1cd-913d8e751c37.png\">",
      "correct_choice_id": 211,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">There is more compliance in 3HP than in 9H and 6H.</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">There is no significant difference in compliance between 3HP, 6H, and 9H.</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">The chance of abortion in 3HP is the same as in 6H.</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">The 3HP regimen is less effective than 6H and 9H in preventing active tuberculosis.</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient is initiated on the 3HP regimen (Isoniazid + Rifapentine once weekly for 3 months) for tuberculosis preventive therapy (TPT). Which of the following statements about the 3HP regimen is true?</span></p>",
      "unique_key": "DT1324859",
      "question_audio": null,
      "question_video": null,
      "map_id": 1324859,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>The 3HP regimen, consisting of a 3-month course of weekly rifapentine and isoniazid, offers higher patient compliance compared to the longer 9H (9-month isoniazid) and 6H (6-month isoniazid) regimens. Its shorter duration improves adherence and minimises the risk of treatment interruptions, enhancing overall effectiveness.</p>\r\n<p><strong>Tuberculosis Prevention Therapy (TPT): </strong>Treatment given to individuals who are at high risk of developing active TB &amp; prevent progression from latent TB infection.</p>\r\n<p><strong>TB prophylaxis is indicated in the following high-risk patient groups:</strong></p>\r\n<ul>\r\n<li>Contacts of open cases who show recent Mantoux conversion.</li>\r\n<li>Children with a sputum-positive TB patient in the family.</li>\r\n<li>Neonate of a tubercular mother.</li>\r\n<li>Patients with leukaemia, diabetes, silicosis or those receiving immunosuppressant medication or those on long-term corticosteroid therapy.</li>\r\n<li>HIV-infected contacts of sputum-positive cases.</li>\r\n</ul>\r\n<p><strong>The recommended regimens for tuberculosis treatment include the following options:</strong></p>\r\n<ul>\r\n<li><strong>6H or 9H:</strong> Isoniazid (5 mg/kg) daily for 6 months (6H) or 9 months (9H).</li>\r\n<li><strong>3HP: </strong>Rifapentine (10 mg/kg) combined with high-dose Isonazid (15 mg/kg) weekly for 3 months.</li>\r\n<li><strong>4R: </strong>Rifampin (10 mg/kg) daily for 4 months.</li>\r\n<li><strong>3HR: </strong>Isoniazid (5 mg/kg) and Rifampin (10 mg/kg) daily for 3 months.&nbsp;</li>\r\n</ul>\r\n<p><strong>The chance of abortion in 3HP is the same as in 6H (Option C): </strong>The difference in the duration of exposure leads to a different side effect profile, and the risk of pregnancy-related complications, including abortion, is not the same in both regimens.&nbsp;</p>\r\n<p><strong>The 3HP regimen is less effective than 6H and 9H in preventing active tuberculosis (Option D): </strong>It is incorrect because 3HP is as effective, if not slightly more effective, in preventing active TB when compared to the longer regimens of 6H and 9H.&nbsp;</p>\r\n<p><strong>Reference:</strong></p>\r\n<ol>\r\n<li><a href=\"https://www.cdc.gov/tb/topic/treatment/ltbi.htm#:~:text=CDC%20and%20the%20National%20Tuberculosis,weekly%20isoniazid%20plus%20rifapentine%20(3HP)\" target=\"_blank\">https://www.cdc.gov/tb/topic/treatment/ltbi.htm#:~:text=CDC%20and%20the%20National%20Tuberculosis,weekly%20isoniazid%20plus%20rifapentine%20(3HP)</a></li>\r\n</ol>",
      "correct_choice_id": 221,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 24,
      "choices": [
        {
          "id": 231,
          "text": "<p><span style=\"font-size:12.0pt;\">Binge eating</span></p>"
        },
        {
          "id": 232,
          "text": "<p><span style=\"font-size:12.0pt;\">Selective mutism</span></p>"
        },
        {
          "id": 233,
          "text": "<p><span style=\"font-size:12.0pt;\">Separation from parents leading to depression</span></p>"
        },
        {
          "id": 234,
          "text": "<p><span style=\"font-size:12.0pt;\">Conduct disorder</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A child with untreated ADHD is most likely to develop which of the following disorders during adolescence?</span></p>",
      "unique_key": "DT1325129",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325129,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Untreated <strong>Attention-Deficit/Hyperactivity Disorder (ADHD)</strong> in childhood is associated with an increased risk of developing <strong>Conduct Disorder</strong> during adolescence.</p>\r\n<ul>\r\n<li>Children with ADHD often display impulsivity, aggression, and difficulty following rules, which may escalate into more severe behavioural problems, including <strong>violating the rights of others</strong> and engaging in <strong>antisocial behaviour</strong>.</li>\r\n</ul>\r\n<p><strong>Explanation for other options:</strong></p>\r\n<p><strong>Binge eating (Option A)</strong> is not typically associated with untreated ADHD, although some individuals with ADHD may engage in emotional eating.</p>\r\n<p><strong>Selective mutism (Option B)</strong> is more commonly associated with anxiety disorders and is not directly linked to ADHD.</p>\r\n<p><strong>Separation from parent leading to depression (Option C)</strong> is not a common progression from ADHD, though emotional difficulties can arise, especially in children with comorbid conditions</p>",
      "correct_choice_id": 234,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}